Funded Pharmaceutical Manufacturing Startups
Among the 7 most recent pharmaceutical manufacturing funding events shown, the largest disclosed round is Egetis Therapeutics AB’s $38M on 2026-04-21, and…
Among the 7 most recent pharmaceutical manufacturing funding events shown, the largest disclosed round is Egetis Therapeutics AB’s $38M on 2026-04-21, and it stands above the other disclosed amounts in this slice (the next-largest disclosed is Lenz Therapeutics at $49M on 2022-11-22, while the rest of disclosed rounds cluster between $23M and $40M). Three disclosures are “undisclosed” (Solvet on 2025-04-08; PannTheraPi on 2023-06-23; India Globalization Capital is the smallest disclosed at $230K on 2026-01-05), creating a clear outlier at the low end alongside the higher disclosed checks from Lenz ($49M, 2022-11-22) and Corsair Pharma ($23M, 2023-09-20).
Geographically, the list is split across the US, Canada, France, and Sweden; the US accounts for 4 of 7 entries (Juniper Biosciences 2025-12-01 $40M; Corsair Pharma 2023-09-20 $23M; India Globalization Capital 2026-01-05 $230K; Lenz Therapeutics 2022-11-22 $49M). Stage-wise, “Series Unknown” appears 4 times (Egetis 2026-04-21; India Globalization Capital 2026-01-05; Solvet 2025-04-08; PannTheraPi 2023-06-23), while only Juniper Biosciences is explicitly Seed ($40M, 2025-12-01) and Corsair Pharma is explicitly Series B ($23M, 2023-09-20). Temporally, the displayed round dates span 2022-11-22 to 2026-04-21, with a concentration in 2025–2026 (4 of 7 rounds).
Most recent rounds
7 shownRelated listings
Frequently asked
What is the largest disclosed funding amount in this pharmaceutical manufacturing snapshot, and how much higher is it than most others?
Lenz Therapeutics’ $49M disclosed round on 2022-11-22 is the highest disclosed amount in the 7-row list. Most other disclosed checks shown sit below that level, including Egetis Therapeutics AB at $38M (2026-04-21), Juniper Biosciences at $40M (2025-12-01), and Corsair Pharma at $23M (2023-09-20).
Are there notable outliers at the low end or due to missing disclosures?
Yes: India Globalization Capital’s smallest disclosed amount is $230K on 2026-01-05, far below the other disclosed rounds (e.g., Corsair Pharma at $23M on 2023-09-20 and Juniper Biosciences at $40M on 2025-12-01). Separately, three entries are “undisclosed” (Solvet on 2025-04-08; PannTheraPi on 2023-06-23; and one other undiscosed amount in the table), so comparisons are limited where amounts aren’t published.
Do the round dates cluster in a recent window?
They do. Four of the 7 rows are dated in 2025–2026 (Juniper Biosciences 2025-12-01; Solvet 2025-04-08; India Globalization Capital 2026-01-05; Egetis Therapeutics AB 2026-04-21), spanning up to the most recent date shown, 2026-04-21.
Which stage/label dominates among the 7 entries?
“Series Unknown” appears 4 times out of 7 (Egetis Therapeutics AB on 2026-04-21; India Globalization Capital on 2026-01-05; Solvet on 2025-04-08; PannTheraPi on 2023-06-23). The remaining disclosed stage labels are Seed for Juniper Biosciences (Seed, 2025-12-01, $40M) and Series B for Corsair Pharma (Series B, 2023-09-20, $23M).
Is there geographic over-representation, or is it evenly spread?
It’s more split than concentrated, but the US is over-represented: 4 of 7 entries list US locations (Juniper Biosciences in Bridgewater, NJ on 2025-12-01; Corsair Pharma in Sunnyvale, CA on 2023-09-20; India Globalization Capital in Bethesda, MD on 2026-01-05; Lenz Therapeutics in Del Mar, CA on 2022-11-22). The rest are Sweden (Egetis, 2026-04-21), Canada (Solvet, 2025-04-08), and France (PannTheraPi, 2023-06-23).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.